Product Details
ORBACTIV PR 400MG 3
Manufacturer: MELINTA THERAPEUTICS INC
MFG#: 70842-0140-03
NDC: 70842-0140-03
PID: 648415
3/CT
$7,115.52
In Stock
$7,115.52
Product Properties:
| Description | S |
|---|---|
| Description | S |
| Description | Oritavancin inj (orbactiv), 10 MG |
| DESI Drug Ind | - |
| DESI Drug Ind | -; - |
| DESI Drug Ind | -; - |
| DESI2 Drug Ind | - |
| Drug Category | S |
| Drug Category | USES: This medication is an antibiotic used to treat serious bacterial infections of the skin. It works by stopping the growth of bacteria. |
| Drug Category | USES: This medication is an antibiotic used to treat serious bacterial infections of the skin. It works by stopping the growth of bacteria. |
| Drug Type Code | COMMON BRAND NAME(S): Kimyrsa, Orbactiv |
| Drug Type Code | COMMON BRAND NAME(S): Kimyrsa, Orbactiv |
| Drug Type Code | 1 |
| FDA Approval Date | 08/06/2014 |
| FDA Therap Equiv | NR |
| HCPCS | J2407 |
| HCPCS | 1 |
| HCPCS | 1 |
| Market Entry Date | 10/08/2014 |
| Medical Coverage | COVERED WITH SPECIAL INSTRUCTIONS |
| Medical Coverage | - |
| Medical Coverage | - |
| Termination Date | (or-IT-a-VAN-sin) |
| Termination Date | (or-IT-a-VAN-sin) |
| Termination Date | - |
| Unit | EA |
| Units Per Pkg | 3 |
| Active Ingredients | 15661 oritavancin diphosphate 192564140 |
| Active Ingredients | 15661 oritavancin diphosphate 192564140 |
| Active Ingredients | 15661 oritavancin diphosphate 192564140 |
| AHFS Class | 8122816 GLYCOPEPTIDE ANTIBIOTICS |
| AHFS Class | 8122816 GLYCOPEPTIDE ANTIBIOTICS |
| AHFS Class | 8122816 GLYCOPEPTIDE ANTIBIOTICS |
| DEA Class | NC |
| DEA Class | NC |
| DEA Class | NC |
| Dose Form | VIAL (EA) |
| Dose Form | VIAL (EA) |
| Dose Form | VIAL (EA) |
| Fine Line Class | 850085008510 All Rx Products |
| Fine Line Class | 850085008510 All Rx Products |
| Fine Line Class | 850085008510 All Rx Products |
| Gen Code and Des | 72732 oritavancin diphosphate INTRAVEN VIAL 400 MG |
| Gen Code and Des | 72732 oritavancin diphosphate INTRAVEN VIAL 400 MG |
| Gen Code and Des | 72732 oritavancin diphosphate INTRAVEN VIAL 400 MG |
| Inactive Ingredients | 2272 mannitol 69658 |
| Inactive Ingredients | 2272 mannitol 69658 |
| Inactive Ingredients | 2272 mannitol 69658 |
| OMP Family | - |
| OMP Family | - |
| OMP Family | - |
| Product Category | RX Pharmaceuticals |
| Product Category | RX Pharmaceuticals |
| Product Category | RX Pharmaceuticals |
| Strength | 400MG |
| Strength | 400MG |
| Strength | 400MG |
| Common Brand Name | J2407 |
| Common Brand Name | J2407 |
| Common Brand Name | COMMON BRAND NAME(S): Kimyrsa, Orbactiv |
| Drug Interaction | DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval. One product that may interact with this drug is: heparin. This medication may interfere with certain lab tests (including blood clotting tests such as PT/INR/aPTT), possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug, and if you are using warfarin or are being treated for bleeding/clotting disorders. |
| Drug Interaction | - |
| Drug Interaction | - |
| Allocation Period | - |
| Allocation Period | - |
| Allocation Period | - |
| Case Quantity | 30 |
| Case Quantity | 30 |
| Case Quantity | 30 |
| Drug Form Pack Size | 3 |
| Drug Form Pack Size | 3 |
| Drug Form Pack Size | 3 |
| Form | VIAL |
| Form | VIAL |
| Form | VIAL |
| Hazard Code | UN3077 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. |
| Hazard Code | UN3077 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. |
| Hazard Code | UN3077 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. |
| Listed Chemical | - |
| Listed Chemical | - |
| Listed Chemical | - |
| NIOSH Code | - |
| NIOSH Code | - |
| NIOSH Code | - |
| Orange Book | ZC Pharmaceutical entity and labeler evaluated but no therapeutic equivalence rating given. Usually applies to single source drugs. |
| Orange Book | ZC Pharmaceutical entity and labeler evaluated but no therapeutic equivalence rating given. Usually applies to single source drugs. |
| Orange Book | ZC Pharmaceutical entity and labeler evaluated but no therapeutic equivalence rating given. Usually applies to single source drugs. |
| Retail Pack Quantity | 1 |
| Retail Pack Quantity | 1 |
| Retail Pack Quantity | 1 |
| Returnable Status | Returnable |
| Returnable Status | Returnable |
| Returnable Status | Returnable |
| Special Storage Cond | 00 None |
| Special Storage Cond | 00 None |
| Special Storage Cond | 00 None |
| Temp Zone | 20 Cool-Store Cont Temp |
| Temp Zone | 20 Cool-Store Cont Temp |
| Temp Zone | 20 Cool-Store Cont Temp |
| Unit | EA |
| Unit | EA |
| Unit | EA |
| Unit Size | 3 |
| Unit Size | 3 |
| Unit Size | 3 |
| How to Use | HOW TO USE: This medication is given by a health care professional as a single dose. Depending on your product, this medication is injected slowly into a vein over 1 or 3 hours. Tell your doctor if your condition lasts or gets worse. |
| How to Use | - |
| How to Use | - |
| Missed Dose | 3 |
| Missed Dose | 3 |
| Missed Dose | MISSED DOSE: Not applicable. |
| Notes | NOTES: Lab and/or medical tests (such as liver function) may be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details. |
| Notes | EA |
| Notes | EA |
| Overdose | NR |
| Overdose | NR |
| Overdose | OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. |
| Phonetic Pronunciation | (or-IT-a-VAN-sin) |
| Phonetic Pronunciation | COVERED WITH SPECIAL INSTRUCTIONS |
| Phonetic Pronunciation | COVERED WITH SPECIAL INSTRUCTIONS |
| Precautions | - |
| Precautions | - |
| Precautions | PRECAUTIONS: Before using oritavancin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using this medication, tell your doctor or pharmacist your medical history. See also Drug Interactions section. Oritavancin may cause live bacterial vaccines (such as typhoid vaccine) to not work well. Tell your health care professional that you are using oritavancin before having any immunizations/vaccinations. Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products). During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding. |
| Side Effects | SIDE EFFECTS: Nausea, vomiting, or headache may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly. Injection reaction symptoms such as flushing of the upper body, hives, itching, back/chest pain, chills, or shaking may also occur. Tell your doctor right away if you have any of these symptoms. Stopping or slowing down the injection may help. Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: bone pain, fast heartbeat, unusual tiredness, swelling ankles/feet/hands. This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped. Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse. Use of this medication for prolonged or repeated periods may result in oral thrush or a new yeast infection. Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345. |
| Side Effects | - |
| Side Effects | - |
| Storage | 08/06/2014 |
| Storage | 08/06/2014 |
| Storage | STORAGE: Not applicable. This medication is given in a hospital and will not be stored at home. |
| Uses | USES: This medication is an antibiotic used to treat serious bacterial infections of the skin. It works by stopping the growth of bacteria. |
| Uses | Oritavancin inj (orbactiv), 10 MG |
| Uses | Oritavancin inj (orbactiv), 10 MG |
Frequently Asked Questions (FAQs)
The cost of ORBACTIV PR 400MG 3 is $$7,115.52
ORBACTIV PR 400MG 3 is manufactured by MELINTA THERAPEUTICS INC.
You can purchase ORBACTIV PR 400MG 3 on our website at https://supplies.pipelinemedical.com/product/detail/orbactiv-400-mg-vl-3-323714